Avantor AVTR recently entered into a strategic partnership with BlueWhale Bio to accelerate innovation in CAR-T cell therapy ...

Dr. John Mellors, who heads the cell therapy discovery team for biotechnology company Galapagos, talks about the innovations the organization is making to improve delivery speed and access to CAR ...

T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments is to ...

Cause-Specific Mortality in a Cohort of 1,435 Patients With Hodgkin Lymphoma Treated Between 1985 and 2014: A Nationwide Chilean Cohort Study Healthy volunteers were recruited and underwent ...

Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technologies industries, today announced a strategic ...

Less than a year after purchasing private cell therapy company ImmPact Bio to help refresh its ailing CAR-T pipeline, manufacturing considerations have prompted Lyell Immunopharma to cut staff at its ...

Chimeric antigen receptor (CAR) T-cell therapy is an innovative cancer treatment that engineers a patient’s own T cells to target and destroy cancer cells. While the field has sparked significant ...

We caught up with the team behind the first ever mobile leukapheresis center to see what community-based care could look like in the world of cell therapies.